Cargando…

IL-19 Contributes to the Development of Nonalcoholic Steatohepatitis by Altering Lipid Metabolism

Interleukin (IL)-19, a member of the IL-10 family, is an anti-inflammatory cytokine produced primarily by macrophages. Nonalcoholic steatohepatitis (NASH) is a disease that has progressed from nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation and fibrosis. We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Azuma, Yasu-Taka, Fujita, Takashi, Izawa, Takeshi, Hirota, Kana, Nishiyama, Kazuhiro, Ikegami, Airi, Aoyama, Tomoko, Ike, Mikihito, Ushikai, Yumi, Kuwamura, Mitsuru, Fujii, Hideki, Tsuneyama, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699936/ https://www.ncbi.nlm.nih.gov/pubmed/34944021 http://dx.doi.org/10.3390/cells10123513

Ejemplares similares

Interleukin-19 Gene-Deficient Mice Promote Liver Fibrosis via Enhanced TGF-β Signaling, and the Interleukin-19-CCL2 Axis Is Important in the Direction of Liver Fibrosis
por: Ono, Naoshige, et al.
Publicado: (2023)

L-arginine-induced pancreatitis aggravated by inhibiting Na(+)/Ca(2+) exchanger 1
por: ONO, Naoshige, et al.
Publicado: (2023)

Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis
por: Atarashi, Machi, et al.
Publicado: (2018)

Fucoxanthin Ameliorates Atopic Dermatitis Symptoms by Regulating Keratinocytes and Regulatory Innate Lymphoid Cells
por: Natsume, Chika, et al.
Publicado: (2020)

Deficiency of interleukin-19 exacerbates lipopolysaccharide/D-galactosamine-induced acute liver failure
por: FUJIMOTO, Yasuyuki, et al.
Publicado: (2020)

Interleukin-19 enhances cytokine production induced by lipopolysaccharide and inhibits cytokine production induced by polyI:C in BALB/c mice
por: AZUMA, Yasu-Taka, et al.
Publicado: (2020)

Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis
por: Matsumoto, Kana, et al.
Publicado: (2022)

Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis
por: Yamaguchi, Takashi, et al.
Publicado: (2022)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Aggregation Causes Mitochondrial Dysfunction during Oxidative Stress-induced Cell Death
por: Nakajima, Hidemitsu, et al.
Publicado: (2017)

Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis
por: Suwa, Kanehiko, et al.
Publicado: (2020)

Gastrointestinal motility modulation by stress is associated with reduced smooth muscle contraction through specific transient receptor potential channel
por: AZUMA, Yasu-Taka, et al.
Publicado: (2021)

Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy
por: Nagaya, Tadanobu, et al.
Publicado: (2015)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

An obese patient with acute cholecystitis, nonalcoholic steatohepatitis and cirrhosis: A case report
por: Zuiki, Toru, et al.
Publicado: (2020)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Correction: Medaka as a model for human nonalcoholic steatohepatitis
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Fructo-oligosaccharides and intestinal barrier function in a methionine–choline-deficient mouse model of nonalcoholic steatohepatitis
por: Matsumoto, Kotaro, et al.
Publicado: (2017)

Effect of tocotrienol on the primary progression of nonalcoholic steatohepatitis in a mouse model
por: Noichi, Jun, et al.
Publicado: (2022)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Serological and Histological Examination of a Nonalcoholic Steatohepatitis Mouse Model Created via the Administration of Monosodium Glutamate
por: Takai, Atsuko, et al.
Publicado: (2014)

Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis
por: Saito, Kosuke, et al.
Publicado: (2015)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
por: Hwang, Seonghwan, et al.
Publicado: (2021)

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
por: Xiang, Hui, et al.
Publicado: (2022)

Human Nonalcoholic Steatohepatitis on a Chip
por: Freag, May S., et al.
Publicado: (2020)

Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1 in a Rat Parkinson’s Disease Model
por: ITAKURA, Masanori, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h0p071251f2e12jusq954n04bn